Crown Settles Customer Dispute To Close $924M Revance Buy

By Al Barbarino · October 28, 2024, 11:01 AM EDT

Revance Therapeutics has settled a distribution-related dispute with customer Teoxane SA, potentially clearing the path for its planned $924 million acquisition by skincare company Crown Laboratories. ...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login